Overview
Location
United States, Illinois, Wilmette
Employees
11-50
Founded date
2014
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 30, 2024 | Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock | WILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet... |
| Oct 29, 2024 | Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock | WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet... |
| Oct 28, 2024 | Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock | WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet... |
| Oct 26, 2024 | Monopar Therapeutics: A High-Stakes Gamble in Biotech | Monopar Therapeutics is riding a rollercoaster. The company’s stock surged over 400% in a single day, fueled by a licensing deal with AstraZeneca. This spike has drawn attention, but it also raises questions. Is this a genuine opportunity o... |
| Oct 25, 2024 | Monopar Therapeutics Skyrockets 400% on Licensing Deal Monopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 drug. | Monopar Therapeutics (NASDAQ: MNPR) saw its stock skyrocket over 400% on Thursday after announcing a licensing deal with AstraZeneca. By 2 PM, the stock had traded over 10 million shares, far above its usual daily volume of 800,000. This s... |
| Mar 5, 2024 | Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program | |
| Oct 4, 2022 | ROTH Capital Partners to Host Inaugural Healthcare Opportunities Conference on October 6th at the Yale Club in New York City | Event to feature company presentations and one-on-one meetings between institutional investors and senior management from select Healthcare companies in Biotechnology, Pharmaceuticals, Medical Technologies, Oncology and Mental Health Therap... |
| Nov 12, 2021 | Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments - Form 8-K | Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments First Patients Dosed in Camsirubicin Phase 1b Clinical Trial in U.S. Validive® Phase 2b/3 VOICE Trial Cleared to Enroll in Europe and on Trac... |
| Aug 12, 2021 | Monopar Therapeutics : Reports Second Quarter 2021 Financial Results and Recent Business Updates (Form 8-K) | Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates Camsirubicin Phase 1b Clinical Trial Anticipated to Start in the U.S. in Q4 2021 Validive®Phase 2b/3 VOICE Trial on Track for Reaching Interim An... |
Reviews 0
FAQ about Monopar Therapeutics Inc. (MNPR)
When was Monopar Therapeutics Inc. (MNPR) founded?
Monopar Therapeutics Inc. (MNPR) was founded in 2014.
What has the press written about Monopar Therapeutics Inc. (MNPR)?
Parsers VC has collected 10 articles mentioning Monopar Therapeutics Inc. (MNPR), among them “Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock” (Oct 30, 2024) and “Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock” (Oct 29, 2024).
Is Monopar Therapeutics Inc. (MNPR) still active?
Yes, Monopar Therapeutics Inc. (MNPR) is active; its latest activity on Parsers VC dates from Nov 8, 2024.